리소스 임상적 특징 [GIOTRIF] In real-world practice, sequential afatinib followed by osimertinib is a feasible and effective therapeutic strategy for EGFR m+ NSCLC patients acquiring T790M during the period of afatinib treatment1 [GIOTRIF] Based on current real-world and clinical trial evidences, the optimal regimen maybe first-line afatinib followed by osimertinib4- [GIOTRIF] Over 1000 published cases of patients with uncommon EGFR M+ NSCLC treated with GIOTRIF® [GIOTRIF] A sequential approach of first-line GIOTRIF® followed by various subsequent treatments can be a feasible and appropriate treatment option for patients with EGFR M+ NSCLC from TOAST study [GIOTRIF] Real-world Outcomes of First-line GIOTRIF® in Patients with Non-small Cell Lung Cancer and Uncommon EGFR Mutations in South Korea 더로드
